Table 1. Patient information.
| Gender | ||
| Male | 315 (68.48%) | |
| Female | 145 (31.52%) | |
| Age at surgery | ||
| ≤ 60 | 272 (59.13%) | |
| > 60 | 188 (40.87%) | |
| Tumor size | ||
| < 4.0 | 66 (14.35%) | |
| ≥ 4.0 | 394 (85.65%) | |
| Tumor location | ||
| Upper third | 113 (24.57%) | |
| Middle third | 118 (25.65%) | |
| Lower third | 201 (43.70%) | |
| More than 2/3 stomach | 28 (6.08%) | |
| Depth of tumor invasion (T stage) | ||
| T1 | 5 (1.09%) | |
| T2 | 46 (10.00%) | |
| T3 | 285 (61.96%) | |
| T4 | 124 (26.95%) | |
| Number of metastatic lymph nodes (N stage) | ||
| N0 | 111 (24.13%) | |
| N1 | 163 (35.44%) | |
| N2 | 107 (23.26%) | |
| N3 | 79 (17.17%) | |
| Location of lymph node metastasis | ||
| No | 111 (24.13%) | |
| Perigastric | 158 (34.35%) | |
| Extragastric | 191 (41.52%) | |
| Lauren classification | ||
| Intestinal | 122 (26.52%) | |
| Diffuse | 320 (69.57%) | |
| Mixed | 18 (3.91%) | |
| Methylated CpG site count | ||
| 1 or less | 193 (41.96%) | |
| 2 or more | 267 (58.04%) | |
| Methylated status of CpG -236 | ||
| Unmethylated | 356 (77.39%) | |
| Methylated | 104 (22.61%) | |
| Methylated status of CpG -183 | ||
| Unmethylated | 301 (65.43%) | |
| Methylated | 159 (34.57%) | |
| Methylated status of CpG -162 | ||
| Unmethylated | 349 (75.87%) | |
| Methylated | 111 (24.13%) | |
| Methylated status of CpG -152 | ||
| Unmethylated | 284 (61.74%) | |
| Methylated | 176 (38.26%) | |